Supportive Care Articles | Page 2

Informed Patients Are More Likely to Choose Palliative Care
Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.
Advances in treatment and supportive care have resulted in substantial improvements in cancer survival and a growing number of cancer survivors in the United States.
The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.
European Commission Approves Oral Rolapitant for CINV
The European Commission has approved oral rolapitant tablets for the treatment of delayed chemotherapy-induced nausea and vomiting in adults.
FDA Eliminates REMS Requirement for ESAs
The FDA has eliminated the need for risk evaluation and mitigation strategy certification prior to the administration of erythropoiesis-stimulating agents for anemia due to myelosuppressive chemotherapy.
FDA Accepts Ibrutinib Application for GVHD
The FDA has accepted a supplemental new drug application for ibrutinib as a treatment for patients with chronic graft-versus-host-disease after failure of 1 or more lines of systemic therapy.
FDA Approves Telotristat Ethyl for Carcinoid Syndrome Diarrhea
The FDA has approved telotristat ethyl (Xermelo) for use in combination with somatostatin analog (SSA) as a treatment for carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors that cannot be adequately controlled by SSA therapy alone.
Rolapitant Recommended for EU Approval for CINV
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of oral rolapitant (Varuby; Varubi in US) for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy.
Prophylactic Letermovir Limits CMV Infections Post-Transplantation
Prophylactic treatment with letermovir lowered the rates of cytomegalovirus infection and all-cause mortality compared with placebo for CMV-seropositive patients following an allogeneic hematopoietic stem cell transplant.
High-User Focus Trims Oncology Tab
It was 15 years ago that Jeffrey Brenner, MD, hypothesized that patients with the highest costs in the Camden, New Jersey, healthcare system received the worst care.
Publication Bottom Border
Border Publication